NovaBridge Biosciences Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 24, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	244	391	67	143	325	3,207
Market Cap Growth	375.86%	484.53%	-53.13%	-56.11%	-89.86%	18.02%
Enterprise Value	66	199	-130	-215	-208	2,564
Last Close Price	2.16	3.34	0.83	1.65	3.34	40.20
PS Ratio	-	-	-	249.50	-223.95	263.21
PB Ratio	1.24	1.99	0.34	0.65	0.82	5.08
P/TBV Ratio	1.24	1.99	0.34	0.65	0.91	5.42
EV/Sales Ratio	-	-	-	-	-	210.43
Debt / Equity Ratio	0.01	0.01	0.02	0.02	0.03	0.03
Net Debt / Equity Ratio	-0.90	-0.90	-0.84	-1.27	-1.16	-0.91
Net Debt / EBITDA Ratio	2.21	2.21	3.31	6.35	9.27	2.02
Net Debt / FCF Ratio	10.08	10.08	1.59	2.10	5.31	4.15
Asset Turnover	-	-	-	0.00	-	0.02
Quick Ratio	7.91	7.91	20.65	5.39	4.60	7.48
Current Ratio	8.09	8.09	20.90	5.67	4.78	7.66
Return on Equity (ROE)	-40.89%	-40.89%	-22.40%	-24.75%	-26.08%	-45.78%
Return on Assets (ROA)	-24.90%	-24.90%	-11.05%	-6.38%	-4.73%	-21.69%
Return on Invested Capital (ROIC)	-330.29%	-343.99%	-	-	-	-338.80%
Return on Capital Employed (ROCE)	-40.40%	-40.40%	-25.20%	-15.80%	-11.00%	-41.60%
Earnings Yield	-30.85%	-19.25%	-32.12%	-131.74%	-106.82%	-10.06%
FCF Yield	-7.20%	-4.49%	-154.11%	-93.01%	-26.58%	-4.33%
Buyback Yield / Dilution	-17.96%	-17.96%	2.45%	-0.86%	-8.63%	-11.11%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.